|Bid||18.33 x 800|
|Ask||18.35 x 900|
|Day's Range||18.12 - 18.60|
|52 Week Range||17.11 - 37.75|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 11, 2020 - Feb 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.55|
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the […]
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00 p.m. ET/5:00 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT).The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
As the momentum in the equity markets is expected to stay on firm-footing in 2020, these five stocks that failed to stand out in 2019 have a chance to outperform next year.
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.